European novel drug research to address microbial infections and drug resistance
Project factsheets
Learn more about the projects supported by IHI as well as the Innovative Medicines Initiative (IMI).
Displaying 19 projects and 2 programmes
Antibiotic distribution and recovery in tissue
Antimicrobial Resistance Accelerator
Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections
Collaboration for prevention and treatment of MDR bacterial infections
European regimen accelerator for tuberculosis
Novel Gram-negative antibiotic now
Predicting the impact of monoclonal antibodies & vaccines on antimicrobial resistance
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments
Academia and industry united innovation and treatment for tuberculosis
The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
Combatting bacterial resistance in Europe - molecules against Gram negative infections
Combatting Bacterial Resistance in Europe
Driving re-investment in R&D and responsible antibiotic use
European Gram-negative Antibacterial Engine
Inhaled antibiotics in bronchiectasis and cystic fibrosis
New Drugs for Bad Bugs
Molecular basis of the bacterial cell wall permeability
